PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016

MarketResearchReports.Biz announces addition of new report “PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016” to its database.

Description

View Full Report at: marketresearchreports.biz/analysis/556851

Programmed Death 1 (PD-1)
Programmed Death Ligand 1 (PD-L1)
Role of PD-1 and PD-L1 pathways
MOA of PD-1 and PD-L1 inhibitors
Significance of PD-1 and PD-L1 inhibitors
PD-1 and PD-L1 Active Therapy Areas & Epidemiology
Metastatic Renal Cell Carcinoma
Squamous Cell Carcinomas of the Head and Neck
Epidemiology
Metastatic Colorectal Cancer
Epidemiology
Non-Small Cell lung cancer
Epidemiology
Biomarkers - PD-1 and PD-L1 inhibitors
Market Overview
Comparative Analysis of Pipeline &Marketed Drugs
Marketed Product of PD-1 and PD-L1 drugs –Overview
Marketed Drug Candidate Profiles
Marketed Drugs Sales
Details of Patent Expiry of Marketed Drugs
Current and Future Market for PD and PD-L1 inhibitors:
Challenges and Barriers associated with use of PD and PD-L1 inhibitors:
PD-1/PD-L1Combinations Creating Boom
Pipeline Therapeutics
An overview of pipeline products
Therapeutics under Development by MOA
Therapeutics under Development by Companies
Late Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Unknown Stages Molecules
Other Companies Inclination towards PD-1/PD-L1 Inhibitors
Therapeutic Assessment of pipeline
Therapeutics under Development by Product Type
Therapeutics under Development by Phase for Monotherapy
Therapeutics under Development by Phase for Combination therapy
Therapeutics under Development by Molecule Type
Therapeutics under Development by Route of Administration
SWOT Analysis

Download Sample Copy of This Report at: marketresearchreports.biz/sample/sample/556851

Table Of Content

Table 1: Marketed and Pipeline drugs forPD-1 and PD-L1 Drugs, 2016
Table 2: PD-1 Marketed Drugs, 2016
Table 3: Sales of Marketed drugs, 2016
Table 4: Details of patent expiry of marketed molecules, 2016
Table 5:Bristol Myers Squibb’s drug-Opdivo (nivolumab) Partners for Combination Therapies
Table 6: Merck’s drug- Keytruda (Pembrolizumab) Partners for Combination Therapies
Table 7:AstraZeneca’s drug- Durvalumab (MEDI4736) Partners for Combination Therapies
Table 8: Roche’s drug-Atezolizumab (MPDL-3280A) Partners for Combination Therapies
Table 9: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2016
Table 10: ComparativeTable forPD-1 and PD-L1 inhibitors Drugs, 2016
Table 11: Number of Products under Development by Companies, 2016
Table12: Late Stage Products (Phase III and Filed), 2016
Table 13: Mid Stage Products (Phase II), 2016
Table 14: Early Stage Products (Phase I and IND), 2016
Table 15: Pre-Clinical and Discovery Products, 2016
Table 16: Number of Products by Product Type for PD-1 and PD-L1 Inhibitors, 2016
Table 17: Number of Monotherapy Products for PD-1 and PD-L1 inhibitors, 2016
Table 18: Number of Combination therapy Products forPD-1 and PD-L1 inhibitors, 2016
Table 19: Number of Products under Development by Molecule Type, 2016
Table 20:Number of Products under Development by Route of Administration, 2016

Browse Latest Industry Press Release at: http://www.marketresearchreports.biz/pressreleases

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Contact
Mr. Nachiket
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

This release was published on openPR.